NCT07288320PHASE2Recruiting
An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania
Neurocrine Biosciences
Start Date
12/24/2025
Completion Date
2/1/2028
Summary
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving manic symptoms in adults with bipolar I disorder who are currently experiencing an episode of mania with or without mixed features.
Eligibility Criteria
Age Range: 18 years to 65 years
Key Inclusion Criteria:
* Participant has a primary diagnosis of bipolar I disorder.
* The participant has had at least 1 prior documented manic episode that required treatment.
* The participant is experiencing an acute manic episode or manic episode with mixed features, with or without psychotic symptoms.
Key Exclusion Criteria:
* Any unstable or poorly controlled medical condition or chronic disease (including history of neurological, hepatic, renal, cardiovascular, gastrointestinal, pulmonary, autoimmune, or endocrine disease that may affect study participation or results), or malignancy within 90 days before the start of screening.
* Primary diagnosis is not bipolar I disorder.
* History of clozapine treatment for treatment-resistant psychosis.
* History of psychiatric hospitalization(s) for ≥30 consecutive days during the 90 days before the start of screening.
Note: Additional inclusion/exclusion criteria may apply, per protocol.
Interventions
DRUG
NBI-1117568
DRUG
Placebo
Conditions
Bipolar I DisorderMania
Locations
Neurocrine Clinical Site
Little Rock, Arkansas 72211
United States
Neurocrine Clinical Site
Garden Grove, California 92845
United States
Neurocrine Clinical Site
San Diego, California 92123
United States
Neurocrine Clinical Site
Hollywood, Florida 33024
United States
Neurocrine Clinical Site
Atlanta, Georgia 30331
United States
Neurocrine Clinical Site
Gaithersburg, Maryland 20877
United States
Neurocrine Clinical Site
Marlton, New Jersey 08053
United States
Neurocrine Clinical Site
Staten Island, New York 10314
United States
Neurocrine Clinical Site
Austin, Texas 78754
United States